REGγ accelerates melanoma formation by regulating Wnt/β‐catenin signalling pathway

It has been reported that the proteasome activator REGγ is associated with multiple oncogenic pathways in human cancers. However, the role of REGγ in the development of melanoma and the underlying mechanisms remain unclear. In this study, we attempted to investigate the effects of REGγ on human melanoma cell proliferation in vitro and in vivo. We demonstrated that knockdown of REGγ inhibited melanoma cell growth and arrested melanoma cell at G1 phase. Furthermore, depletion of REGγ also inhibited the xenograft growth of human melanoma. Mechanistically, REGγ activates Wnt/β‐catenin signal pathway by degrading GSK‐3β in melanoma cell lines and mouse models. Transient knockdown of β‐catenin effectively blocked cell proliferation in REGγ wild‐type melanoma cells. In human melanoma samples, REGγ was overexpressed and positively correlated with β‐catenin levels. This study demonstrates that REGγ is a central molecule in the development of melanoma by regulating Wnt/β‐catenin pathway. This suggests that targeting REGγ could be an alternative therapeutic approach for melanoma.

[1]  R. Moses,et al.  REGγ is critical for skin carcinogenesis by modulating the Wnt/β-catenin pathway , 2015, Nature Communications.

[2]  You-hong Cui,et al.  High expression of REGγ is associated with metastasis and poor prognosis of patients with breast cancer. , 2014, International journal of clinical and experimental pathology.

[3]  C. Creighton,et al.  PKA turnover by the REGγ-proteasome modulates FoxO1 cellular activity and VEGF-induced angiogenesis. , 2014, Journal of molecular and cellular cardiology.

[4]  Jing Hu,et al.  Regulation of Wnt/β-catenin signaling by posttranslational modifications , 2014, Cell & Bioscience.

[5]  Yunbo Shi,et al.  The Mesobuthus martensii genome reveals the molecular diversity of scorpion toxins , 2014, Cell & Bioscience.

[6]  L. Donehower,et al.  REGγ deficiency promotes premature aging via the casein kinase 1 pathway , 2013, Proceedings of the National Academy of Sciences.

[7]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[8]  A. Veerman,et al.  Myeloid Antigen Expression in Childhood Acute Lymphoblastic Leukemia and Its Relevance for Clinical Outcome in Indonesian ALL-2006 Protocol , 2012, Journal of oncology.

[9]  F. Tas Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors , 2012, Journal of oncology.

[10]  Tieliu Shi,et al.  REGγ is associated with multiple oncogenic pathways in human cancers , 2012, BMC Cancer.

[11]  Katherine M White,et al.  A randomised controlled trial of a theory-based intervention to improve sun protective behaviour in adolescents ('you can still be HOT in the shade'): study protocol , 2012, BMC Cancer.

[12]  C. Garbe,et al.  β-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and Chemoresistance , 2011, PloS one.

[13]  H. Mukhtar,et al.  Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels. , 2011, The Journal of investigative dermatology.

[14]  Guowu Yu,et al.  Comparative analysis of REG{gamma} expression in mouse and human tissues. , 2010, Journal of molecular cell biology.

[15]  Y. Matsuura,et al.  Involvement of PA28γ in the propagation of hepatitis C virus , 2010, Hepatology.

[16]  R. Moon,et al.  Wnt and Related Signaling Pathways in Melanomagenesis , 2010, Cancers.

[17]  R. Moon,et al.  Activated Wnt/ß-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model , 2009, Proceedings of the National Academy of Sciences.

[18]  P. Nuciforo,et al.  Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. , 2008, Cancer research.

[19]  Ruiwen Zhang,et al.  Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation , 2008, The EMBO journal.

[20]  B. O’Malley,et al.  Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. , 2007, Molecular cell.

[21]  A. Malovannaya,et al.  The SRC-3/AIB1 Coactivator Is Degraded in a Ubiquitin- and ATP-Independent Manner by the REGγ Proteasome , 2006, Cell.

[22]  I. Hisatome,et al.  Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  M. Sheikh,et al.  Melanoma: Molecular Pathogenesis and Therapeutic Management. , 2014, Molecular and cellular pharmacology.

[24]  L. Larue,et al.  The WNT/Beta-catenin pathway in melanoma. , 2006, Frontiers in bioscience : a journal and virtual library.